Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications

Praneet Kumar; Gary S. Francis; W. H. Wilson Tang

doi:10.1038/nrcardio.2009.32

Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications

Praneet Kumar
, Gary S. Francis
, W. H. Wilson Tang

Medicine - Cardiology Division

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.

Original language	English (US)
Pages (from-to)	349-355
Number of pages	7
Journal	Nature Reviews Cardiology
Volume	6
Issue number	5
DOIs	https://doi.org/10.1038/nrcardio.2009.32
State	Published - May 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/nrcardio.2009.32

Find It

Find It at U of M Libraries

Cite this

@article{4db3ee5485944869a09b42aed902a636,

title = "Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications",

abstract = "Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.",

author = "Praneet Kumar and Francis, \{Gary S.\} and \{Wilson Tang\}, \{W. H.\}",

year = "2009",

month = may,

doi = "10.1038/nrcardio.2009.32",

language = "English (US)",

volume = "6",

pages = "349--355",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Research",

number = "5",

}

TY - JOUR

T1 - Phosphodiesterase 5 inhibition in heart failure

T2 - Mechanisms and clinical implications

AU - Kumar, Praneet

AU - Francis, Gary S.

AU - Wilson Tang, W. H.

PY - 2009/5

Y1 - 2009/5

N2 - Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.

AB - Phosphodiesterase 5 (PDE5) selectively hydrolyzes cyclic guanosine monophosphate. Inhibitors of PDE5 were originally developed to treat angina pectoris, and currently have multiple therapeutic indications, including erectile dysfunction and pulmonary hypertension. several lines of research have provided evidence to support various potential PDE5-dependent cellular mechanisms in the myocardium that are involved in the pathophysiology of heart failure and cardiac dysfunction. In this Review we provide a mechanistic overview of the pharmacological inhibition of PDE5 in the context of heart failure, and evaluate the evidence supporting the use of novel PDE5 inhibitors in the treatment of this condition.

UR - https://www.scopus.com/pages/publications/67649566083

UR - https://www.scopus.com/pages/publications/67649566083#tab=citedBy

U2 - 10.1038/nrcardio.2009.32

DO - 10.1038/nrcardio.2009.32

M3 - Review article

C2 - 19377497

AN - SCOPUS:67649566083

SN - 1759-5002

VL - 6

SP - 349

EP - 355

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 5

ER -

Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this